Mackenzie Financial
PSTX

Mackenzie Financial’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Mackenzie Financial’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,616
Closed -$50.4K – 1807
2024
Q3 		$50.4K Hold
17,616
– – ﹤0.01% 1535
2024
Q2 		$51.4K Buy
+17,616
New +$48.2K ﹤0.01% 1490
2024
Q1 		– Sell
-13,514
Closed -$45.4K – 1623
2023
Q4 		$45.4K Sell
13,514
-2,400
-15% -$6.18K ﹤0.01% 1451
2023
Q3 		$35.8K Sell
15,914
-2,918
-15% -$6.12K ﹤0.01% 1433
2023
Q2 		$32.6K Buy
+18,832
New +$48.1K ﹤0.01% 1483

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Mackenzie Financial's PSTX Position: Q4 2024 in Review

Mackenzie Financial sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 17,616 shares — an estimated $50.4K sold.

Mackenzie Financial first reported a position in PSTX in Q2 2023 and held it in 5 quarters. The position peaked at $51.4K in Q2 2024. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

  • Mackenzie Financial reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Mackenzie Financial sold 17,616 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $50.4K.
  • Mackenzie Financial first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2023 and held it in 5 quarters.
  • Mackenzie Financial's Poseida Therapeutics, Inc. Common Stock position peaked at $51.4K in Q2 2024.
  • 115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Mackenzie Financial's 13F filing for Q4 2024, filed 14 Feb 2025.